Weiss, Michael D. http://orcid.org/0000-0003-4064-1032
Freimer, Miriam
Leite, M. Isabel
Maniaol, Angelina
Utsugisawa, Kimiaki
Bloemers, Jos
Boroojerdi, Babak
Howard, Emily
Savic, Natasa
Howard, James F. Jr
Funding for this research was provided by:
UCB Pharma
Article History
Received: 18 December 2023
Revised: 10 January 2024
Accepted: 16 January 2024
First Online: 24 February 2024
Declarations
:
: Michael D. Weiss has received honoraria for serving on scientific advisory boards for Alexion Pharmaceuticals, Immunovant, Ra Pharmaceuticals (now UCB Pharma), argenx, Biogen, Mitsubishi Tanabe Pharma and Amylyx; consulting honoraria from Cytokinetics and CSL Behring and speaker honoraria from Soleo Health. He also serves as a special government employee for the Food and Drug Administration. Miriam Freimer has served as a paid Consultant for argenx, UCB Pharma and Alexion Pharmaceuticals. She receives research support from the NIH, UCB Pharma, Janssen Pharmaceuticals, Alnylam, Avidity and Fulcrum. M. Isabel Leite is funded by the NHS (Myasthenia and Related Disorders Service and National Specialised Commissioning Group for Neuromyelitis Optica, UK) and by the University of Oxford, UK. She has been awarded research grants from the UK association for patients with myasthenia (Myaware) and the University of Oxford. She has received speaker honoraria or travel grants from Biogen, Novartis, UCB Pharma and the Guthy-Jackson Charitable Foundation. She serves on scientific or educational advisory boards for UCB Pharma, argenx and Viela Bio (now Horizon Therapeutics). Angelina Maniaol has received payment for travel, meeting attendance, consulting honoraria or advisory board participation from CSL Behring, Novartis, Biogen, argenx and UCB Pharma. Kimiaki Utsugisawa has served as a paid Consultant for UCB Pharma, argenx, Janssen Pharmaceuticals, Viela Bio (now Horizon Therapeutics), Chugai Pharmaceutical, HanAll Biopharma, Merck and Mitsubishi Tanabe Pharma. He has received speaker honoraria from argenx, Alexion Pharmaceuticals, UCB Pharma and the Japan Blood Products Organization. Jos Bloemers, Babak Boroojerdi and Natasa Savic are employees and shareholders of UCB Pharma. Emily Howard was an employee of Cogent working for UCB Pharma on a contract basis. James F. Howard Jr has received research support (paid to his institution) from Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI and UCB Pharma; honoraria from AcademicCME, Alexion AstraZeneca Rare Disease, argenx, Biologix Pharma, CheckRare CME, F. Hoffmann-La Roche, Horizon Therapeutics (now Amgen), MedScape CME, Merck EMD Serono, NMD Pharma, Novartis, PeerView CME, Physicians’ Education Resource (PER) CME, PlatformQ CME, Regeneron Pharmaceuticals, Sanofi US, UCB Pharma and Zai Labs; and non-financial support from Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, Toleranzia AB, UCB Pharma and Zai Labs.
: This study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice. Institutional review boards or independent ethics committees provided written approval for the study protocol and all amendments. All patients provided written informed consent.